--- title: "United Therapeutics to Present New Clinical Data on Pulmonary Hypertension and Inhaled Treprostinil at CHEST 2025 Annual Meeting" description: "United Therapeutics Corporation will present new clinical data on pulmonary hypertension and inhaled treprostinil at the CHEST 2025 Annual Meeting in Chicago from October 19-22, 2025. The presentation" type: "news" locale: "en" url: "https://longbridge.com/en/news/260882441.md" published_at: "2025-10-13T11:00:34.000Z" --- # United Therapeutics to Present New Clinical Data on Pulmonary Hypertension and Inhaled Treprostinil at CHEST 2025 Annual Meeting > United Therapeutics Corporation will present new clinical data on pulmonary hypertension and inhaled treprostinil at the CHEST 2025 Annual Meeting in Chicago from October 19-22, 2025. The presentations will include interim analysis results from the PHINDER Study and data on inhaled treprostinil's impact on hospitalizations in PH-ILD patients. The company will also sponsor events, including a symposium on PH-ILD management and the Women in Chest Medicine Annual Luncheon. United Therapeutics Corporation announced that it will feature new clinical data at the upcoming CHEST 2025 Annual Meeting, scheduled for October 19-22, 2025, in Chicago. The company will present two oral presentations, including interim analysis results from the PHINDER Study on echocardiographic features of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), and data on the impact of inhaled treprostinil initiation timing on hospitalizations in PH-ILD patients. These results will be presented at the meeting and have not yet been disclosed publicly. United Therapeutics will also sponsor several events at the conference, such as a symposium on best practices in PH-ILD detection and management, and the Women in Chest Medicine Annual Luncheon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013658816) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) ### Related Stocks - [UTHR.US - United Therap](https://longbridge.com/en/quote/UTHR.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | MidWestOne Financial Group Inc. 增加了对联合治疗公司 $UTHR 的持股量 | MidWestOne Financial Group Inc. 在第三季度将其在联合治疗公司（NASDAQ: UTHR）的持股增加了 741.9%，目前持有 9,446 股，价值 396 万美元。其他投资者也调整了他们的持股，贝塞默集团和阿 | [Link](https://longbridge.com/en/news/275976913.md) | | 联合治疗公司总裁兼首席运营官 Michael Benkowitz 报告了出售普通股的情况 | 联合治疗公司（United Therapeutics Corporation）的总裁兼首席运营官 Michael Benkowitz 已报告出售该公司的普通股。完整的文件可通过提供的链接获取。此新闻简报由公共技术公司生成，仅供信息参考，不应 | [Link](https://longbridge.com/en/news/275513269.md) | | Leuthold Group LLC 收购了 7,546 股联合治疗公司 $UTHR | Leuthold Group LLC 在第三季度收购了 7,546 股联合治疗公司（NASDAQ: UTHR），价值约为 316 万美元。其他机构投资者也增加了他们在 UTHR 的持股。分析师对该股票的共识评级为 “适度买入”，目标价格为 | [Link](https://longbridge.com/en/news/275762494.md) | | Ashton Thomas Private Wealth LLC 出售了 United Therapeutics Corporation 的股票，股票代码为$UTHR | Ashton Thomas Private Wealth LLC 在第三季度减少了对联合治疗公司的持股，减幅达到 79.7%，目前持有 2,012 股，价值 843,000 美元。其他机构投资者也调整了他们的持股，Geneos Wealth | [Link](https://longbridge.com/en/news/275221303.md) | | 路德会的 Thrivent Financial 持有联合治疗公司价值 7411 万美元的股票 | Thrivent Financial for Lutherans 在第三季度减少了对联合治疗公司的持股比例，下降了 4.7%，目前持有 176,787 股，价值 7411 万美元。其他对冲基金也调整了他们的持仓，挪威银行和英维斯公司（Inv | [Link](https://longbridge.com/en/news/274484821.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.